BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 16690721)

  • 1. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.
    Lim YC; Li L; Desta Z; Zhao Q; Rae JM; Flockhart DA; Skaar TC
    J Pharmacol Exp Ther; 2006 Aug; 318(2):503-12. PubMed ID: 16690721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
    Lim YC; Desta Z; Flockhart DA; Skaar TC
    Cancer Chemother Pharmacol; 2005 May; 55(5):471-8. PubMed ID: 15685451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
    Osipo C; Gajdos C; Cheng D; Jordan VC
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines.
    Vendrell JA; Bieche I; Desmetz C; Badia E; Tozlu S; Nguyen C; Nicolas JC; Lidereau R; Cohen PA
    Endocr Relat Cancer; 2005 Mar; 12(1):75-92. PubMed ID: 15788640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
    Itoh T; Karlsberg K; Kijima I; Yuan YC; Smith D; Ye J; Chen S
    Mol Cancer Res; 2005 Apr; 3(4):203-18. PubMed ID: 15831674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.
    Johnson MD; Zuo H; Lee KH; Trebley JP; Rae JM; Weatherman RV; Desta Z; Flockhart DA; Skaar TC
    Breast Cancer Res Treat; 2004 May; 85(2):151-9. PubMed ID: 15111773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.
    Revillion F; Pawlowski V; Lhotellier V; Louchez MM; Peyrat JP
    Anticancer Res; 2003; 23(2B):1455-60. PubMed ID: 12820409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation.
    Zheng Y; Sun D; Sharma AK; Chen G; Amin S; Lazarus P
    Drug Metab Dispos; 2007 Oct; 35(10):1942-8. PubMed ID: 17620345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of VDR-responsive gene signatures in breast cancer cells.
    Towsend K; Trevino V; Falciani F; Stewart PM; Hewison M; Campbell MJ
    Oncology; 2006; 71(1-2):111-23. PubMed ID: 17377416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells.
    Wang Z; Kyo S; Maida Y; Takakura M; Tanaka M; Yatabe N; Kanaya T; Nakamura M; Koike K; Hisamoto K; Ohmichi M; Inoue M
    Oncogene; 2002 May; 21(22):3517-24. PubMed ID: 12032853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
    Wu X; Hawse JR; Subramaniam M; Goetz MP; Ingle JN; Spelsberg TC
    Cancer Res; 2009 Mar; 69(5):1722-7. PubMed ID: 19244106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
    Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
    Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of antiestrogens and medroxyprogesterone acetate on the clonogenic growth of tamoxifen-sensitive and resistant human breast cancer cells].
    Nomura Y; Tashiro H; Takaeko F
    Gan To Kagaku Ryoho; 1985 Apr; 12(4):844-50. PubMed ID: 3157351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.
    Maximov PY; McDaniel RE; Fernandes DJ; Bhatta P; Korostyshevskiy VR; Curpan RF; Jordan VC
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25258390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.
    Frasor J; Chang EC; Komm B; Lin CY; Vega VB; Liu ET; Miller LD; Smeds J; Bergh J; Katzenellenbogen BS
    Cancer Res; 2006 Jul; 66(14):7334-40. PubMed ID: 16849584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen metabolite isomer separation and quantification by liquid chromatography-tandem mass spectrometry.
    Jaremko M; Kasai Y; Barginear MF; Raptis G; Desnick RJ; Yu C
    Anal Chem; 2010 Dec; 82(24):10186-93. PubMed ID: 21086978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance.
    Thomas NB; Hutcheson IR; Campbell L; Gee J; Taylor KM; Nicholson RI; Gumbleton M
    Breast Cancer Res Treat; 2010 Feb; 119(3):575-91. PubMed ID: 19288272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro cytotoxicity of 4'-OH-tamoxifen and estradiol in human endometrial adenocarcinoma cells HEC-1A and HEC-1B.
    Cuevas ME; Lindeman TE
    Oncol Rep; 2015 Jan; 33(1):464-70. PubMed ID: 25351552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score.
    Barginear MF; Jaremko M; Peter I; Yu C; Kasai Y; Kemeny M; Raptis G; Desnick RJ
    Clin Pharmacol Ther; 2011 Oct; 90(4):605-11. PubMed ID: 21900890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.